Skip to content

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
$0.47-9.6%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$1.22+31.2%
Viatris logo
ViatrisVTRS
$0.15+106%
Opko Health logo
Opko HealthOPK
-$0.07+30.0%
AptarGroup logo
AptarGroupATR
$1.12-4.3%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
-$0.61-74.3%

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.4%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's EPS (diluted)?
Amphastar Pharmaceuticals (AMPH) reported EPS (diluted) of $0.14 in Q1 2026.
How has Amphastar Pharmaceuticals's EPS (diluted) changed year-over-year?
Amphastar Pharmaceuticals's EPS (diluted) decreased by 72.5% year-over-year, from $0.51 to $0.14.
What is the long-term trend for Amphastar Pharmaceuticals's EPS (diluted)?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's EPS (diluted) has grown at a 12.9% compound annual growth rate (CAGR), from $1.25 to $2.03.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.